View of A Proof-of-Concept Study for an Intradermal Dose-Sparing Strategy: Non-Inferior Immunogenicity and Improved Systemic Tolerability of Fractional-Dose ChAdOx1-S SARS-CoV-2 Vaccine Compared to Intramuscular Administration

Return to Article Details A Proof-of-Concept Study for an Intradermal Dose-Sparing Strategy: Non-Inferior Immunogenicity and Improved Systemic Tolerability of Fractional-Dose ChAdOx1-S SARS-CoV-2 Vaccine Compared to Intramuscular Administration Download Download PDF